Immunome Inc. (IMNM) — SEC Filings
Immunome Inc. (IMNM) — 48 SEC filings. Latest: 4 (Mar 31, 2026). Includes 25 8-K, 6 10-Q, 5 SC 13G.
View Immunome Inc. on SEC EDGAR
Overview
Immunome Inc. (IMNM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Mar 31, 2026: On March 27, 2026, Clay B. Siegall, a reporting person for Immunome Inc., reported a change in beneficial ownership of securities. The filing details transactions related to Immunome Inc. stock, with specific details on the nature of the transaction and the number of shares involved not fully disclo
Sentiment Summary
Across 48 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 41 neutral, 5 mixed. The dominant filing sentiment for Immunome Inc. is neutral.
Filing Type Overview
Immunome Inc. (IMNM) has filed 2 4, 25 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G, 5 SC 13G/A, 1 SC 13D/A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (48)
Risk Profile
Risk Assessment: Of IMNM's 32 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $6.9M |
| Net Income | -$142.5M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $272.6M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Clay B. Siegall
- IM-1021
- IM-3050
- Isaac Barchas
- Dr. P. Ann S. Smith
- Dr. Jonathan M. Rothberg
- Clay B. Siegall, Ph.D.
- P. Ann C. Lee
- Dr. David M. Weiner
- Abigail P. Johnson
Industry Context
Immunome operates in the highly competitive and capital-intensive biotechnology sector, focusing on the discovery and development of novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on innovation, pipeline progression, and the ability to secure substantial funding to navigate clinical trials and regulatory approvals.
Top Tags
financials (7) · operations (6) · corporate-governance (5) · sec-filing (4) · 8-k (4) · biotech (4) · material-agreement (3) · form-4 (2) · Biotechnology (2) · Oncology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-39580 | Identifies the company's filing history with the SEC. |
| EIN | 77-0694340 | Employer Identification Number for tax purposes. |
| Cash and cash equivalents | $272.6M | Increased from $143.4M at Dec 31, 2024, providing liquidity. |
| Net loss for nine months | $142.5M | Improved from $212.7M in prior year, driven by lower IPR&D. |
| Research and development expenses for nine months | $126.5M | Increased from $81.7M in prior year, reflecting pipeline investment. |
| Accumulated deficit | $658.3M | As of September 30, 2025, indicating historical losses. |
| Shares outstanding | 91,710,277 | As of November 3, 2025, reflecting recent equity issuances. |
| Proceeds from public offering | $161.7M | Net of commissions and offering costs, bolstering cash. |
| Proceeds from ATM offering | $44.9M | Net of issuance costs, contributing to increased liquidity. |
| Collaboration revenue for nine months | $6.9M | Slight increase from $6.3M in prior year, but still minimal. |
| Net Loss (Q2 2025) | $25.2M | Increased from $16.8M in Q2 2024, reflecting higher R&D. |
| Net Loss (YTD Q2 2025) | $49.7M | Increased from $32.9M in YTD Q2 2024, indicating rising operational costs. |
| R&D Expenses (Q2 2025) | $20.1M | Up from $13.2M in Q2 2024, driven by clinical trial activities for IM-1021 and IM-3050. |
| Gross Proceeds from Offering | $100.0M | Raised in January 2025, significantly improving liquidity. |
| Accumulated Deficit | $350.2M | As of June 30, 2025, highlighting the company's pre-revenue stage and historical losses. |
Forward-Looking Statements
- {"claim":"Immunome Inc.'s stock price may experience downward pressure or increased volatility in the short term.","entity":"Immunome Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Other institutional investors might re-evaluate their positions in Immunome Inc. following this disclosure.","entity":"Institutional Investors","targetDate":"Q2 2024","confidence":"medium"}
- {"claim":"Immunome Inc. may experience increased investor confidence and potentially a positive stock price movement due to FMR LLC's significant stake.","entity":"Immunome Inc.","targetDate":"short-term","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Immunome Inc. (IMNM)?
Immunome Inc. has 48 recent SEC filings from Jan 2024 to Mar 2026, including 25 8-K, 6 10-Q, 5 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IMNM filings?
Across 48 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 41 neutral, 5 mixed. The dominant sentiment is neutral.
Where can I find Immunome Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Immunome Inc. (IMNM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Immunome Inc.?
Key financial highlights from Immunome Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IMNM?
The investment thesis for IMNM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Immunome Inc.?
Key executives identified across Immunome Inc.'s filings include Clay B. Siegall, IM-1021, IM-3050, Isaac Barchas, Dr. P. Ann S. Smith and 5 others.
What are the main risk factors for Immunome Inc. stock?
Of IMNM's 32 assessed filings, 1 were flagged high-risk, 14 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Immunome Inc.?
Recent forward-looking statements from Immunome Inc. include guidance on {"claim":"Immunome Inc.'s stock price may experience downward pressure or increased volatility in the short term.","enti and 2 other predictions.